---
layout: default
title: Alectinib Hydrochloride 161 33 Mg Eqv Alectinib
parent: 僅模型預測 (L5)
nav_order: 56
evidence_level: L5
indication_count: 0
---

# Alectinib Hydrochloride 161 33 Mg Eqv Alectinib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Alectinib: Evaluation Halted — Insufficient Evidence Pack Data

## One-Sentence Summary

Alectinib hydrochloride is a second-generation ALK (Anaplastic Lymphoma Kinase) tyrosine kinase inhibitor, internationally approved for ALK-positive non-small cell lung cancer (NSCLC).
The current Evidence Pack contains **no TxGNN-predicted repurposing indications**, **zero Singapore regulatory registrations**, and **critical data gaps in MOA and safety**, making a standard repurposing evaluation impossible at this stage.
This report documents the gap findings and outlines the remediation steps required before a full evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | ALK-positive NSCLC (identified from INN; not present in regulatory data) |
| Predicted New Indication | Not available — `predicted_indications` array is empty |
| TxGNN Prediction Score | Not available |
| Evidence Level | Not assessable |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Is Available

The TxGNN pipeline was run against the drug string `"ALECTINIB HYDROCHLORIDE 161.33 MG EQV. ALECTINIB"`. The DrugBank query returned a match (`result_count: 1`), but no `drugbank_id` was populated in the output, and `predicted_indications` remains empty. This typically occurs when the pipeline cannot resolve the compound's canonical identity — likely because the input string contains a dosage quantity rather than a clean INN.

Alectinib is a highly selective, CNS-penetrant ALK inhibitor with a well-characterized pharmacological profile. Its potential for repurposing into other ALK-driven malignancies (e.g., ALK-positive anaplastic large cell lymphoma, inflammatory myofibroblastic tumor) is biologically plausible. However, without a valid TxGNN output, no formal prediction can be evaluated or scored.

Detailed mechanism of action data was not returned in the Evidence Pack (Data Gap DG002). Based on publicly available pharmacology, alectinib inhibits ALK and RET kinases, preventing downstream RAS/MAPK and PI3K/AKT signalling that drives tumour proliferation and survival.

---

## Clinical Trial Evidence

Currently no related clinical trials are registered in this Evidence Pack.

---

## Literature Evidence

Currently no related literature is available in this Evidence Pack.

---

## Singapore Market Information

Alectinib is not currently registered with Singapore's HSA. No license records are available in the regulatory database extract.

> **Note:** Alectinib (Alecensa®) has regulatory approval in the US (FDA, 2015/2017), EU (EMA), and Japan (PMDA). HSA Singapore approval status should be independently verified via the HSA PRISM portal before concluding "not registered."

---

## Cytotoxicity

Alectinib meets the antineoplastic classification criteria (cancer indication, targeted kinase inhibitor class).

| Item | Content |
|------|---------|
| Cytotoxicity Classification | Targeted therapy — ALK/RET tyrosine kinase inhibitor (not a conventional cytotoxic) |
| Myelosuppression Risk | Low to moderate; anaemia is the most common haematological adverse effect |
| Emetogenicity Classification | Low |
| Monitoring Items | LFTs (AST, ALT, bilirubin), CBC, creatine phosphokinase (CPK), serum creatinine, ECG (QTc) |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information.

> Both key warnings and contraindications are listed as Data Gap (DG001 — Blocking severity). No DDI interactions were found in the query log. Safety evaluation cannot proceed until the package insert is retrieved and parsed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is structurally incomplete — no TxGNN predictions, no Singapore regulatory records, and two blocking data gaps (DG001, DG002) prevent any component of the standard evaluation from being completed. Proceeding to a repurposing decision without these inputs would be speculative.

**To proceed, the following is needed:**

- **Resolve DrugBank mapping** — re-run the pipeline with the clean INN `"alectinib"` (without dose quantity) to obtain a valid `drugbank_id` and trigger TxGNN prediction output
- **Retrieve package insert** (DG001 — Blocking) — download and parse the approved SmPC/PI from FDA.gov, EMA, or PMDA to populate warnings and contraindications
- **Populate MOA data** (DG002 — High) — query DrugBank API with the resolved ID to obtain mechanism of action, targets, and pharmacodynamic class
- **Verify Singapore HSA registration** — cross-check HSA PRISM portal directly; the pipeline returned zero records but international approval is documented
- **Re-run TxGNN pipeline** with corrected input string and confirm `predicted_indications` is populated before re-initiating this evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

